Upstream Bio, Inc. (UPB)
2.74
-0.25
(-8.36%)
USD |
NASDAQ |
Oct 23, 16:00
2.735
0.00 (0.00%)
After-Hours: 20:00
Upstream Bio Gross Profit Margin (Quarterly) : 93.53% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.53% |
| March 31, 2026 | 95.26% |
| December 31, 2025 | 91.47% |
| September 30, 2025 | 95.46% |
| Date | Value |
|---|---|
| June 30, 2025 | 93.92% |
| March 31, 2025 | 92.40% |
| December 31, 2024 | 92.01% |
| September 30, 2024 | 97.69% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Sutro Biopharma, Inc. | 87.17% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -45.97% |
| Return on Assets | -44.34% |
| Return on Invested Capital | -45.80% |
| Profit Margin (Quarterly) | -5.14K% |
| Operating Margin (Quarterly) | -5.48K% |
| Return on Net Operating Assets | -895.9% |